—
C+
C+ The full Closelook — membership. Open the C+ overview

Exelixis Inc (EXEL) — chart, structure and Closelook read

Home› Indices›
Pick a ticker to load its detail page.

Company snapshot — Exelixis Inc

EXEL in five paragraphs: what it makes and sells, where it sits in the Closelook stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
Exelixis is an oncology company that discovers, develops and sells medicines for hard-to-treat cancers, mainly in the United States. Its main product, CABOMETYX, treats advanced renal cell carcinoma after prior anti-angiogenic therapy, while COMETRIQ addresses progressive medullary thyroid cancer; both derive from cabozantinib, a multi-target kinase inhibitor. COTELLIC, a MEK inhibitor, is combined with other drugs for advanced melanoma, and MINNEBRO treats hypertension in Japan. The company also runs an early pipeline of kinase and antibody-drug-conjugate candidates, including zanzalintinib, often through collaborations with larger pharmaceutical partners such as Roche, Takeda and Bristol-Myers Squibb.
Where it sits in the stack
Exelixis carries no seat in our Rubin AI build-out index. It sits in the healthcare sector, within the biotechnology sleeve of our wider universe, tracked by the diary as a drug-development name outside the AI stack.
Who it is priced against
The diary has no peer group set for Exelixis in this instance; it operates among oncology-focused biotechnology firms, and the wider market often names Bristol-Myers Squibb as a comparable oncology drugmaker.
Why Closelook tracks it
Exelixis holds a seat in the Russell 1000. It does not yet carry a Closelook score, and the diary has not recorded any quotes or editions for it so far.
What the diary watches
The diary watches how sales of CABOMETYX hold up as other firms target the same anti-angiogenic pathway, and how early pipeline candidates such as zanzalintinib move through trials.

Exelixis Inc (EXEL) trades on US exchanges.

Written from the company’s public profile and Closelook’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

Signals for this name

Every Closelook reading that exists for EXEL, from the same nightly bakes the boards use. Research diary readings, not advice.

The Street on this name 2 analyst actions on the wire · latest: price target by Market Perform into patent cliff, 2026-08-18

The Street on this name

Analyst actions and the latest print for EXEL from the Closelook wires — third-party opinions on the record, not our readings.

  • Price target Market Perform into patent cliff — target 54 Target set to $54 (+1.7% to spot) 2026-08-18
  • Initiation BMO Capital — at Market Perform Initiated to Market Perform from Market Perform 2026-08-18

2 actions on the analyst wire since 2026-08-13: 1 initiation, 1 target change. Analyst wire → · Earnings wire →

Who it is priced against Biotechnology · United States · 8 names with week and year-to-date

Peer group

Biotechnology · United States

This name carries no Closelook score, so its cohort ranks on trend state — distance to the 50- and 200-day averages — never on a score it does not have.

Compared against EXEL on the nightly bakes; the Peers tab ranks the cohort on the Closelook scores where it exists.

Weather around the name 3 macro readings: Money Temperature, Factor regime, Sovereign pressure

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 50/100 · S&P 500 fund at 49, above its 50- and 200-day averagesEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-09-18
  • Factor regime Momentum leading — risk appetite buildingMomentum against low volatility (SPMO / SPLV): above its 50-day trend, 97th percentile of the window, +4.9% over 20 sessions. Factor regime → 2026-09-18
  • Sovereign pressure Index 0.07 · down 0.41 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-09-18

FAQ · from the current data · as of 2026-09-19

Quick answers

What is Exelixis Inc (EXEL)?

Exelixis Inc trades as EXEL on the US exchange (United States) in the Closelook research universe, as of the registry build of 2026-09-19.

Is EXEL in a Closelook index?

Not currently — Exelixis Inc is tracked in the Closelook research universe but is not a constituent of a Closelook functional index as of 2026-09-19.

Where does EXEL trade against its moving averages?

Uptrend stack intact: Trades +5.4% vs the 50-day and +20.8% vs the 200-day average, 2.3% below the 52-week high and +72.9% off the 52-week low. Computed from daily closes. As of 2026-09-18 — a technical state from the nightly Closelook bake, not advice. The Technical tab carries the full row.

What does Exelixis Inc do?

Exelixis is an oncology company that discovers, develops and sells medicines for hard-to-treat cancers, mainly in the United States. Its main product, CABOMETYX, treats advanced renal cell carcinoma after prior anti-angiogenic therapy, while COMETRIQ addresses progressive medullary thyroid cancer; both derive from cabozantinib, a multi-target kinase inhibitor. COTELLIC, a MEK inhibitor, is combined with other drugs for advanced melanoma, and MINNEBRO treats hypertension in Japan. The diary has no peer group set for Exelixis in this instance; it operates among oncology-focused biotechnology firms, and the wider market often names Bristol-Myers Squibb as a comparable oncology drugmaker.

Where does Exelixis Inc sit in the AI build-out?

Exelixis carries no seat in our Rubin AI build-out index. It sits in the healthcare sector, within the biotechnology sleeve of our wider universe, tracked by the diary as a drug-development name outside the AI stack. Exelixis holds a seat in the Russell 1000. It does not yet carry a Closelook score, and the diary has not recorded any quotes or editions for it so far.

What has Wall Street done on Exelixis Inc recently?

The most recent analyst action on Exelixis Inc on the Closelook wire is a price target by Market Perform into patent cliff on 2026-08-18 (target 54). 2 actions on the analyst wire since 2026-08-13: 1 initiation, 1 target change. Analyst actions are third-party opinions recorded by the wire, not Closelook readings. The “The Street on this name” block on this page lists the moves; the full feeds are the analyst wire and the earnings wire.

What does this page show?

A live price chart with SMA overlays and drawing tools for EXEL, performance metrics, index-membership context and the Closelook structure read — an investment research diary view, not investment advice.

Related in the Closelook universe

then Biotechnology. Scored names rank on their Closelook score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.